MedTrace Logo

Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell

NCT06575374 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-01-21

No results posted yet for this study

Summary

The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.

Conditions

  • Cell Therapy

Interventions

DRUG

Letermovir

Given by mouth or intravenously

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • George Chen, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2026-08-01
Completion
2027-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06575374 on ClinicalTrials.gov